Articles related to THROMBOLYTIC THERAPY

Tenecteplase administered up to 24 hours after stroke onset improved functional outcomes in patients with large-vessel occlusion and salvageable brain tissue who lacked access to immediate thrombectomy.

In a Chinese study, tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days compared to standard treatment, though it carried a higher risk of symptomatic intracranial hemorrhage.

In a randomized trial of 1,412 patients with acute ischemic stroke, reteplase was more likely to result in excellent functional outcomes at 90 days compared to alteplase.

In a recent trial, late administration of tenecteplase, from 4.5 to 24 hours post-stroke onset, did not demonstrate a significant advantage over placebo in improving the functional outcomes of patients, as measured by the modified Rankin scale at 90 days.